NatureRevClinOncol
@NatRevClinOncol
Followers
40,339
Following
249
Media
1,275
Statuses
14,218
The latest clinical diagnostic, treatment & personalized medicine advances & more from Nature Reviews Clinical Oncology, a reviews journal. Tweets by the eds.
London, UK
Joined August 2011
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Mother's Day
• 1199583 Tweets
Mauro
• 143323 Tweets
Emma
• 67324 Tweets
Nuggets
• 63185 Tweets
#DebateChilango
• 60949 Tweets
Wolves
• 45568 Tweets
Juliana
• 35474 Tweets
Denver
• 33104 Tweets
Sebastián
• 30403 Tweets
Jokic
• 29331 Tweets
Iztapalapa
• 29024 Tweets
Clara Brugada
• 26702 Tweets
Minnesota
• 25464 Tweets
つばさの党
• 25448 Tweets
Jamal Murray
• 24382 Tweets
BIRTH Campaign
• 23328 Tweets
Bruins
• 22340 Tweets
Cruz Azul
• 21274 Tweets
Pumas
• 20635 Tweets
Fabra
• 19993 Tweets
Bennett
• 18757 Tweets
Panthers
• 18600 Tweets
Medina
• 16255 Tweets
Benito Juárez
• 16003 Tweets
Gobert
• 14913 Tweets
家宅捜索
• 12885 Tweets
Tigres
• 12636 Tweets
政治団体
• 12457 Tweets
衆院東京15区
• 11741 Tweets
In a Review now online,
@NicoleKuderer
,
@ADesaiMD
,
@maryam_lustberg
and
@gary_lyman
explain the most common acute toxicities in patients with cancer receiving chemotherapy and discuss management options:
19
293
630
In a Review now published online, Mikael Pittet, Olivier Michielin & Denis Migliorini discuss the clinical relevance of macrophages in cancer, both as biomarkers and in therapeutic approaches
1
91
281
In a new Review
@AndrewChowMDPhD
@KarloPerica
@KlebanoffLab
&
@wolchokj
discuss the immunobiology and clinical implications of T cell exhaustion for cancer immunotherapy:
@MSKCancerCenter
@WeillCornell
0
57
206
In a new Review online in time for weekend reading, Wolf Fridman and colleagues discuss 'B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome':
#ImmunoOnc
#camicroenv
1
76
203
In a Review now published online,
@RohanKatipally
@SeanPitroda
@ajuloorimd
@Docace911
and
@rweichselbaum
provide the current knowledge on oligometastatic cancer
#metastasis
2
71
175
In a Review now online, Patricia Steeg discusses the role of the blood–tumour barrier in cancer biology and therapy
2
67
170
New Review by Douglas Johnson, Caroline Nebhan, Javid Moslehi (
@CardioOncology
) & Justin Balko now live online: 'Immune-checkpoint inhibitors: long-term implications of toxicity'
#ImmunoOnc
#medonc
0
59
169
This new Review describes the roles of dendritic cells (DCs) as orchestrators of anticancer immunity, focusing on novel insights on DC heterogeneity gleaned from single-cell studies & how this knowledge might be leveraged to improve immunotherapy:
5
56
166
In the phase III externally controlled trial of autologous tumour lysate-loaded DC vaccination (DCVax-L) vs SoC for newly diagnosed or recurrent glioblastoma demonstrates promising median OS durations & meaningful increases in the tails of the OS curves:
2
45
163
In a new Perspective, Walia, Tuia &
@VPrasadMDMPH
discuss the adoption of composite end points in oncology, their pro and cons, and advocate for separate reporting of component events to enable a better understanding of cancer biology and trial results:
1
56
162
In a Review now published online, Steven Albelda provides an overview of what we know so far about CAR T cell therapies for solid tumours and proposes strategies to improve outcomes:
1
53
147
New Review by
@BraunMdPhD
@ZiadBakouny
,
@VanAllenlab
,
@DrChoueiri
and colleagues: 'Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma'
@DanaFarber
0
50
145
Online now: Cancer,
#COVID19
and the precautionary principle: prioritizing treatment during a global pandemic, a Comment in which Tim Hanna, Gerald Evans and Chris Booth propose a framework for oncology services during the pandemic
1
76
133
New Review by Mohamed Abou-el-Enein and colleagues now live online: 'Immunogenicity of CAR T cells in cancer therapy' -
#ImmunoOnc
#hemeonc
0
46
131
Now live online, Gideon Blumenthal & Richard Pazdur discuss the FDA approvals in 2018, highlighting 'a histology-agnostic new molecular entity, novel end points and real-time review' -
0
92
128
New Review by Fred Hirsch and coauthors now live online: 'PD-L1 as a biomarker of response to immune-checkpoint inhibitors' -
#ImmunoOnc
0
40
130
In a News and Views now published online, Alexander Frankell and Mariam Jamal-Hanjani from
@TheCrick
discuss a trial of MRD detection after surgery in non-small-cell
#lungcancer
that was published in
@CD_AACR
0
25
118
New Review by Jiajie Hou, Michael Karin & Beicheng Sun now live online: 'Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?' -
#ImmunoOnc
#caxtx
#camicroenv
1
31
121
New Review by Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, Laurence Zitvogel & Guido Kroemer now live online: 'Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors' -
#ImmunoOnc
1
52
117
In a new Review now live online, Yang Chen, Kathleen M. McAndrews & Raghu Kalluri discuss the 'Clinical and therapeutic relevance of cancer-associated fibroblasts':
#btsm
#PancSM
#camicroenv
#caxtx
2
44
113
The 3rd most popular long article published in
@NatRevClinOncol
in 2021 discusses the treatment landscape for triple negative breast cancer
0
32
113
New Review by
@DrJohnSuh
,
@Rrkotecha
,
@SamuelChaoMD
,
@BrainTumorDoc
and colleagues now live online: 'Current approaches to the management of brain metastases'
#camets
0
77
110
Now online, new Review from
@DralexGva
@VivekSubbiah
@Al3ssandroRusso
@gbanna74
@UmbertoMalapel1
@ChristianRolfo
and
@Alfdoc2
on EGFR and HER2 exon 20 insertions in solid tumours, such a timely topic with the recent approval of mobocertinib
1
36
111
New Review by
@SarwishRafiq
Christopher Hackett & Renier Brentjens now live online: 'Engineering strategies to overcome the current roadblocks in CAR T cell therapy' -
@WinshipAtEmoryis
@sloan_kettering
#ImmunoOnc
0
58
108
The 2nd most popular short article published in
@NatRevClinOncol
in 2021 provides insight on T cell exhaustion in the microenvironment
1
33
110
New article by
@VanAllenLab
and
@DrChoueiri
: 'Dissecting the immunogenomic biology of cancer for biomarker development' -
#kcsm
#ImmunoOnc
0
27
111
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer:
#ImmunoOnc
0
36
110
In a Review now published online, Liangfang Zhang et al. describe what cell membrane-coated nanoparticles are and discuss potential therapeutic applications in oncology:
1
36
106
In a new Review now published online, Josep Llovet et al. discuss the immune microenvironments of hepatocellular carcinomas of various aetiologies and the current and future landscape of immunotherapy for this disease:
#ImmunoOnc
#medonc
#hpbcsm
0
45
107
In a new Review now live online, Ignacio Melero, Aurelien Marabelle
@champiatMD
and colleagues discuss 'Intratumoural administration and tumour tissue targeting of cancer immunotherapies':
@GustaveRoussy
@ClinicaNavarra
@CIMA_unav
@idisnanavarra
@CIBERONC
1
37
107
New Review by Stephen Baylin and colleagues now live online: 'The emerging role of epigenetic therapeutics in immuno-oncology' -
1
69
104
In the last few days of 2020 we are compiling a list of the most downloaded
@NatRevClinOncol
articles this year.
#5
is an article on nanomedicines and the tumour microenvironment by Stylianopoulos, Jain and cols.
0
34
104
In a Review now published online,
@FilippoDallOlio
@BenjaminBesseMD
et al. discuss tumour burden, a concept often poorly understood, focusing on its assessment and value as a biomarker in patients receiving ICIs
1
36
103
Another new Review is online today: 'The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches' by Moritz Wildgruber and colleagues -
0
67
101
In a new Review,
@ChristianFluge1
,
@Majzner_Lab
, Giedre Krenciute, Gianpietro Dotti, Stanley Riddell,
@dlwagner13
&
@abouelem
discuss approaches to overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours:
#hemeonc
#ImmunoOnc
0
48
101
Hope you are enjoying our article countdown! The 6th most popular long article published in
@NatRevClinOncol
in 2021 discusses the role of the MYC oncogene in cancer
0
20
101
A single-cell atlas of breast cancer reveals tumour and immune cell diversity and, in addition, highlights presence of PD-L1+ macrophages and exhausted T cells in many ER+ and ER- cancers
0
51
99
In a Review now published online, Guilherme Harada, Soo-Ryum Yang,
@emilianoCocco2
and
@alexdrilon
discuss some molecular subtypes of
#lungcancer
that, despite occurring in <5% of patients with this cancer type, affect a considerable number of individuals
5
40
100
In a new Review now online,
@merghout
@wolchokj
et al.
at
@parkerici
.org
@Ludwig_Cancer
and
@sloan_kettering
discuss emerging immunomodulatory pathways to be targeted in cancer
#Immunotherapy
0
30
100
What do we know about LDH in cancer? In a Review now published online, Caroline Robert and co-authors describe this enzyme from oncological, biochemical, biological and immunological perspectives:
0
43
101
In a new Review now live online,
@drdeansingleton
, Andrew Macann & William Wilson discuss 'Therapeutic targeting of the hypoxic tumour microenvironment':
@ACSRC_UoA
#radonc
#caxtx
#camicroenv
2
31
99
In a new Review, Izuma Nakayama, Changsong Qi, Yang Chen, Yoshiaki Nakamura, Lin Shen & Kohei Shitara discuss Claudin 18.2 as a novel target for cancer therapy:
0
29
99
New Review by Michael J. Grant, Roy S. Herbst & Sarah B. Goldberg
@YaleCancer
now live online: 'Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC' -
#lcsm
#ImmunoOnc
#medonc
0
38
100
In a Review now online,
@g_mountzios
@JordiRemon
@HendriksLizza
Rosario García-Campelo
@ChristianRolfo
Paul Van Schil
@FordePatrick
@BenjaminBesseMD
@VivekSubbiah
@MartinReck2
@jsoriamd
@peters_solange
comprehensively review perioperative ICIs
#lungcancer
0
43
98
New Review by Neil Vasan & Lewis Cantley: 'At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy' -
@CantleyLab
@NeilVasan
1
34
96
New Review by Hirohito Yamaguchi, Jung-Mao Hsu, Wen-Hao Yang & Mien-Chie Hung now live online: 'Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics' -
#ImmunoOnc
#caxtx
0
38
93
In a new Review, Shogo Kumagai, Kota Itahashi & Hiroyoshi Nishikawa discuss new insights on Treg cell-mediated immunosuppressive networks in cancer, presenting the concept of immuno-genomic cancer evolution and a related paradigm for precision medicine:
0
32
96
New Review by Jake O’Donnell, Michele Teng & Mark Smyth now live online: 'Cancer immunoediting and resistance to T cell-based immunotherapy' -
1
61
90
New Review now live - 'Monitoring immune-checkpoint blockade: response evaluation and biomarker development' -
0
86
93
A single-cell transcriptomic analysis of 55 neoantigen-specific TCR clonotypes from 10 metastatic human tumours revealed NeoTCR signatures that enable successful TCR prediction based purely on TIL transcriptomic states for use in cancer immunotherapy:
0
28
91
In a Review now published online, Laura Morrison, Sibylle Loibl & Nicholas C. Turner provide an overview on the role of CDK4/6 inhibitors in current approaches to treat patients with
#breastcancer
and discuss ongoing challenges in this area
0
30
84
New Review by Bertrand Allard, David Allard, Laurence Buisseret & John Stagg now live online: 'The adenosine pathway in immuno-oncology'
#ImmunoOnc
#caxtx
1
41
90
Would you be able to tell the differences between a CD28 and a 4-1BB costimulatory domain in CAR T cells? Kathryn M. Cappell and James N. Kochenderfer address this question in a Review now published
0
31
91
New Perspective article by Satyen Gohil, Bryan Iorgulescu, David Braun, Derin Keskin & Kenneth Livak now live online: 'Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy'
#ImmunoOnc
#camicroenv
#cagenome
1
21
88
We have another new Review live online today: 'HER2-targeted therapies — a role beyond breast cancer' by Do-Youn Oh & Yung-Jue Bang -
0
59
87
In a new Review now live online, Michael Green, Leng Han and co-author discuss the opportunities to advance CAR T cell therapy through the use of multidimensional omics data, as well as the associated challenges:
#ImmunoOnc
#cagenome
#cametab
#caproteo
0
29
88
New Comment article by Jennifer Gill &
@VPrasadMDMPH
- 'A reality check of the accelerated approval of immune-checkpoint inhibitors'
#ImmunoOnc
2
48
89
In a Review now published online,
@maryam_lustberg
@NicoleKuderer
@ADesaiMD
@crisbergerot
and
@gary_lyman
discuss the mitigation of long-term toxicities from cancer treatment, including financial toxicity and psychosocial needs:
0
36
85
Another new Review, live online. In this one,
@alexdrilon
and co-authors discuss the topic of 'MET-dependent solid tumours — molecular diagnosis and targeted therapy'
#caxtx
0
40
86
Santa just came! The 7th most popular
@NatRevClinOncol
long article is freely available this month
0
21
86
Systematic analysis using real-world clinicogenomics data identifies 458 mutations that predict survival with specific immunotherapies, chemotherapy agents or targeted therapies across 8 common cancer types, also revealing mutation–mutation interactions:
0
36
86
In a Perspective now published online, Martina Ott, Robert Prims and Amy Heimberger discuss the immune landscape of
#CNS
cancers and its implications for
#immunotherapy
2
26
87
New Review by Jacob Myers & Jeffrey Miller now live online: 'Exploring the NK cell platform for cancer immunotherapy' -
#ImmunoOnc
1
29
85
New Review by Klaus Pantel & Catherine Alix-Panabières now live online: 'Liquid biopsy and minimal residual disease — latest advances and implications for cure'
1
54
84
new online: Jay Loeffler and colleagues discuss the safety of combinations of radiotherapy with immune-checkpoint blockade
3
65
81
In an update of the SABR-COMET trial of metastasis-directed therapy with SABR vs SOC palliative treatment in pts with solid tumours & 1–5 metastases, 8-year OS was 27.2% vs 13.6% (HR 0.50; P = 0.008). 8-year PFS was 21.3% vs 0.0% (HR 0.45; P <0.001):
1
26
81
In a new Perspective now online,
@VivekSubbiah
and the other members of the COVID19 and Cancer Clinical Trials Working Group provide
#COVID
-19 vaccine guidance for patients with cancer participating in oncology clinical trials:
#Covid_19
#covid19
1
42
82
New Perspective article by Caroline Robert, Aurelien Marabelle, Hugo Herrscher, Caroline Caramella, Pascal Rouby, Karim Fizazi & Benjamin Besse now live: 'Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm' -
#melsm
#ImmunoOnc
0
52
80
New comprehensive Review by
@alexdrilon
,
@MonikaDavare
and colleagues from
@sloan_kettering
and
@OHSUSOM
now live online: 'ROS1-dependent cancers — biology, diagnostics and therapeutics'
#LCSM
#caxtx
#camoldx
#medonc
1
40
78
Another new Review now live online. In this article, Eryn Blass & Patrick Ott discuss 'Advances in the development of personalized neoantigen-based therapeutic cancer vaccines':
@DanaFarber
@BrighamWomens
@harvardmed
@broadinstitute
#ImmunoOnc
#camicroenv
0
33
76
In a News and Views now online, Lopez de Rodas and Schalper discuss two recent articles discussing tumour-infiltrating effector cell function and published in
@Nature
@NatResCancer
0
32
78
Multi-omics analysis of samples from 88 pts with melanoma receiving ICIs suggests that a high TMB and high IFNγ signature predicts response (89% sensitivity, 53% specificity, AUC 0.84). No consistent mechanisms of resistance was seen among non-responders:
0
26
79
In a Review now published online,
@MJ_Mair
and other experts
@MedUni_Wien
@EANOassociation
(and other affiliations) provide an overview on the intracranial activity of andibody-drug conjugates:
0
31
77
New Review by
@ankitkdutta
,
@JbAlberge
,
@RomanosSP
, Elizabeth Lightbody,
@gaddyg
&
@IreneGhobrial
now live: 'Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine'
@DanaFarberNews
#MMSM
#cagenome
#hemeonc
1
26
75
new review online: Ping-Chih Ho and co-authors discuss how knowledge of metabolic pathways can enhance anti-tumour immunity
0
34
78
New Review by Michael F. Berger & Elaine R. Mardis now live online: 'The emerging clinical relevance of genomics in cancer medicine' -
#cagenome
#PrecisionMedicine
#camoldx
1
50
74
Now live, new Review from Lorenz Hofbauer, Klaus Pantel et al. Novel approaches to target the microenvironment of bone
#metastasis
3
22
76
Interesting talk on PARP inhibition and synthetic lethality in
#AACR21
- you can learn more about these processes in this Review from 2018
0
21
75
In a this new Review,
@Kenta_Oncology
,
@natasharekhtman
,
@AlvaroQuintanal
&
@charlesrudin
discuss the convergent biology of neuroendocrine neoplasms of the lung and gastrointestinal system, which might present a path to better therapies:
#lcsm
#NETsm
0
29
75
In a new Review, now live online, Lasse Kristensen, Theresa Jakobsen, Henrik Hager & Jørgen Kjems discuss 'The emerging roles of circRNAs in cancer and oncology', as well as controversies in this field of research:
0
20
75
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients reveals mutation hotspots and unexpected differences in mutation spectrum based on age of diagnosis, MSI status, and colon versus rectum subsite:
#CRCSM
1
52
72
We have another new Review now live online: 'Regulatory T cells in cancer immunosuppression — implications for anticancer therapy' by Yosuke Togashi, Kohei Shitara & Hiroyoshi Nishikawa
#ImmunoOnc
1
43
73
New Review by Won Jin Ho, Elizabeth Jaffee & Lei Zheng now live online: 'The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities'
#PancSM
#camicroenv
0
35
71
In a new Review now live online, Ann Tivey, Matt Church, Dominic Rothwell, Caroline Dive & Natalie Cook discuss advances and potential clinical applications for the analysis of circulating tumour DNA — looking beyond the blood:
#camoldx
0
30
72
In a new Review now live online, Katoh et al. discuss the clinical activity, mechanisms of resistance and new directions of FGFR-targeted therapeutics:
0
22
73
In a Review now published online, Xingcai Zhang and co-authors present the potential of thermal immuno-nanomedicines in oncology
0
19
70
Meta-analysis suggests that even a 4week delay of cancer treatment is associated with increased mortality across surgical, systemic treatment, and radiotherapy indications for seven cancers (bladder, breast, colon, rectum, lung, cervix, & head and neck):
4
30
70
New Review by
@JoshDragoMD
Shanu Modi &
@chandarS_mskcc
now live online: 'Unlocking the potential of antibody–drug conjugates for cancer therapy'
@sloan_kettering
0
21
70